Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ: SPRC )

0.6781 +0.0351 (+5.46%)
Streaming Delayed Price Updated: 3:54 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,909,706
Open 0.6701
Bid (Size) 0.6780 (5)
Ask (Size) 0.6781 (1)
Prev. Close 0.6430
Today's Range 0.5952 - 0.7001
52wk Range 0.6380 - 15.86
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
From SciSparc Ltd
Via GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
From SciSparc Ltd
Via GlobeNewswire

Performance

YTD
-86.68%
-86.68%
1 Month
-26.76%
-26.76%
3 Month
-44.42%
-44.42%
6 Month
-79.88%
-79.88%
1 Year
-95.09%
-95.09%

More News

Read More
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
Mizuho Just Issued a Warning on Palantir (PLTR) Stock
Via InvestorPlace
Why Is SciSparc (SPRC) Stock Up 25% Today?
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
From SciSparc Ltd
Via GlobeNewswire
Why WD-40 Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
From SciSparc Ltd
Via GlobeNewswire
SciSparc Secures Strategic Advantage with Grant of European Patent
From SciSparc Ltd
Via GlobeNewswire
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Macatawa Bank Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
SciSparc To Acquire AutoMax, A Strategic Leap Towards Industry Diversification
Via Benzinga
SciSparc to Acquire AutoMax
From SciSparc Ltd
Via GlobeNewswire
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
From SciSparc Ltd
Via GlobeNewswire
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
From SciSparc Ltd
Via GlobeNewswire
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors
Via Benzinga
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
From SciSparc Ltd
Via GlobeNewswire
Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.